Dear Lauren E. Ingram:

Please refer to your new drug application (NDA) dated and received June 24, 2022, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Litfulo (ritlecitinib) capsule.

This NDA provides for the use of Litfulo (ritlecitinib) capsule for the treatment of severe alopecia areata (AA) in adults and adolescents 12 years and older.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling May 26, 2023, as soon as they are available, but no more

1 http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.
than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry SPL Standard for Content of Labeling Technical Qs & As. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved NDA 215830.” Approval of this submission by FDA is not required before the labeling is used.

**DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Litfulo (ritlecitinib) capsule shall be 30 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

**ADVISORY COMMITTEE**

Your application for Litfulo was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to less than 6 years because necessary studies are impossible or highly impracticable.

We are deferring submission of your pediatric studies for ages 6 to less than 12 years for this application because this product is ready for approval for use in adults and the pediatric studies have not been completed.

Your deferred pediatric studies required by section 505B(a) of the Federal Food, Drug, and Cosmetic Act (FDCA) are required postmarketing studies. The status of these postmarketing studies must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the FDCA. These required studies are listed below.

**4463-1**

Conduct the open-label long-term extension (LTE) study to evaluate the safety of ritlecitinib in pediatric subjects 6 to <12 years of age with moderate to severe alopecia areata who have completed previous ritlecitinib studies B7981031 or B7981027 and are eligible to receive ritlecitinib. Study subjects from B7981031 and placebo subjects from
B7981027 will be randomly assigned to one of the two dose levels to be administered in this study and study subjects who received active drug in B7981027 will remain on the same dosage level they were assigned. All subjects will receive ritlecitinib for up to an additional 3 years.

Final Protocol Submission: 06/2024
Study Completion: 06/2030
Final Report Submission: 12/2030

4463-2 Conduct a randomized, double-blind, placebo-controlled study to investigate the safety of ritlecitinib in pediatric subjects (6 to <12 years of age) with moderate to severe AA (defined by \( \geq 50\% \) scalp hair loss, measured by a SALT score of 50 or greater).

Final Protocol Submission: 06/2024
Study Completion: 05/2027
Final Report Submission: 11/2027

4463-3 Submit the final study report for a PK study which aims to compare the systemic exposures of the dose/regimen in adults and adolescents to that of pediatric subjects ages 6 to <12 years with moderate to severe alopecia areata. Provide data on at least 12 evaluable subjects.

Final Protocol Submission: 11/2022 (submitted)
Study Completion: 02/2024
Final Report Submission: 08/2024

FDA considers the term final to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.3

Submit the protocol(s) to your IND 131503 with a cross-reference letter to this NDA. Reports of these required pediatric postmarketing studies must be submitted as an NDA or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission.

This product is appropriately labeled for use in ages 12 years and older for this indication. Therefore, no additional studies are needed in this pediatric group.

---

3 See the guidance for Industry Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).
U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
POSTMARKETING REQUIREMENTS UNDER 505(o)

Section 505(o)(3) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute.

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify unexpected serious risks, including risks in pregnant females exposed to Litfulo and their newborns.

Furthermore, the active postmarket risk identification and analysis system as available under section 505(k)(3) of the FDCA will not be sufficient to assess potential serious risk(s).

Therefore, based on appropriate scientific data, FDA has determined that you are required to conduct the following studies:

4463-4  Submit the final study report for an ongoing open-label long-term study to investigate the safety of ritlecitinib in adults and adolescents with AA (12 years of age and older).

The timetable you submitted on June 15, 2023, states that you will conduct this study according to the following schedule:

- Final Protocol Submission: 04/2019 (submitted)
- Study Completion: 02/2026
- Final Report Submission: 08/2026

4463-5  Collect data from a prospective pregnancy exposure registry, preferably a disease-based multiproduct pregnancy registry, using a cohort analysis that compares the maternal, fetal, and infant outcomes of women with alopecia areata exposed to ritlecitinib during pregnancy with unexposed comparator population(s). Align the study protocol with protocol(s) outside the US to reach the target sample size. The registry will identify and record pregnancy complications, major and minor congenital malformations, spontaneous abortion, stillbirths, elective terminations, preterm births, small-for-gestational-age births, and any other adverse outcomes, including postnatal growth and development. Outcomes described in the protocol will be assessed throughout pregnancy. Infant outcomes, including effects on postnatal growth and development, will be assessed through at least the first year of life.
The timetable you submitted on June 15, 2023, states that you will conduct this study according to the following schedule:

Draft Protocol Submission: 12/2023  
Final Protocol Submission: 06/2024  
Study Completion: 06/2034  
Final Report Submission: 06/2035

Conduct an additional pregnancy study that uses a different design from the pregnancy exposure registry (for example a retrospective cohort study using claims or electronic medical record data or a case control study) to assess major congenital malformations, spontaneous abortions, stillbirths, and small for gestational age and preterm birth in women exposed to ritlecitinib during pregnancy compared to an unexposed control population.

The timetable you submitted on June 15, 2023, states that you will conduct this study according to the following schedule:

Draft Protocol Submission: 12/2023  
Final Protocol Submission: 06/2024  
Study Completion: 06/2034  
Final Report Submission: 06/2035

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.4

Submit clinical protocol(s) to your IND 131503 with a cross-reference letter to this NDA. Submit nonclinical and chemistry, manufacturing, and controls protocols and all final report(s) to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

**Required Postmarketing Protocol Under 505(o), Required Postmarketing Final Report Under 505(o), Required Postmarketing Correspondence Under 505(o).**

Submission of the protocol(s) for required postmarketing observational studies to your IND is for purposes of administrative tracking only. These studies do not constitute clinical investigations pursuant to 21 CFR 312.3(b) and therefore are not subject to the IND requirements under 21 CFR part 312.

---

4 See the guidance for Industry Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019).

U.S. Food and Drug Administration
Silver Spring, MD 20993

www.fda.gov
Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B(a)(1) of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B(a)(1) and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.*

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

---

5 For the most recent version of a guidance, check the FDA guidance web page at [https://www.fda.gov/media/128163/download](https://www.fda.gov/media/128163/download).

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
POST APPROVAL FEEDBACK MEETING

New molecular entities qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application.

COMPELLDIAL STANDARDS

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP’s website.

If you have any questions, call Jennifer Harmon, Regulatory Project Manager, at 240-402-4880.

Sincerely,

{See appended electronic signature page}

Julie Beitz, MD  
Director  
Office of Immunology and Inflammation  
Office of New Drugs  
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling  
  - Prescribing Information  
  - Medication Guide  
- Carton and Container Labeling

8 https://www.uspnf.com/
U.S. Food and Drug Administration  
Silver Spring, MD 20993  
www.fda.gov
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JULIE G BEITZ
06/23/2023 05:04:10 PM